Literature DB >> 32938692

Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501 022 adult individuals.

Alessandro Mantovani1, Graziana Petracca1, Giorgia Beatrice1, Herbert Tilg2, Christopher D Byrne3, Giovanni Targher4.   

Abstract

OBJECTIVE: Follow-up studies have shown that non-alcoholic fatty liver disease (NAFLD) is associated with an increased risk of incident diabetes, but currently, it is uncertain whether this risk changes with increasing severity of NAFLD. We performed a meta-analysis of relevant studies to quantify the magnitude of the association between NAFLD and risk of incident diabetes.
DESIGN: We systematically searched PubMed, Scopus and Web of Science databases from January 2000 to June 2020 using predefined keywords to identify observational studies with a follow-up duration of at least 1 year, in which NAFLD was diagnosed by imaging techniques or biopsy. Meta-analysis was performed using random-effects modelling.
RESULTS: 33 studies with 501 022 individuals (30.8% with NAFLD) and 27 953 cases of incident diabetes over a median of 5 years (IQR: 4.0-19 years) were included. Patients with NAFLD had a higher risk of incident diabetes than those without NAFLD (n=26 studies; random-effects HR 2.19, 95% CI 1.93 to 2.48; I 2 =91.2%). Patients with more 'severe' NAFLD were also more likely to develop incident diabetes (n=9 studies; random-effects HR 2.69, 95% CI 2.08 to 3.49; I 2 =69%). This risk markedly increased across the severity of liver fibrosis (n=5 studies; random-effects HR 3.42, 95% CI 2.29 to 5.11; I 2=44.6%). All risks were independent of age, sex, adiposity measures and other common metabolic risk factors. Sensitivity analyses did not alter these findings. Funnel plots did not reveal any significant publication bias.
CONCLUSION: This updated meta-analysis shows that NAFLD is associated with a ~2.2-fold increased risk of incident diabetes. This risk parallels the underlying severity of NAFLD. © Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  diabetes mellitus; liver; meta-analysis; nonalcoholic steatohepatitis

Mesh:

Year:  2020        PMID: 32938692     DOI: 10.1136/gutjnl-2020-322572

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  41 in total

Review 1.  Association of metabolic dysfunction-associated fatty liver disease with kidney disease.

Authors:  Ting-Yao Wang; Rui-Fang Wang; Zhi-Ying Bu; Giovanni Targher; Christopher D Byrne; Dan-Qin Sun; Ming-Hua Zheng
Journal:  Nat Rev Nephrol       Date:  2022-01-10       Impact factor: 28.314

2.  Long-term outcomes in patients with non-alcoholic fatty liver disease: further evidence that a multidisciplinary and patient-centred approach to treatment is needed.

Authors:  Giovanni Targher
Journal:  Hepatobiliary Surg Nutr       Date:  2022-02       Impact factor: 7.293

Review 3.  Metabolic mechanisms for and treatment of NAFLD or NASH occurring after liver transplantation.

Authors:  Amedeo Lonardo; Alessandro Mantovani; Salvatore Petta; Amedeo Carraro; Christopher D Byrne; Giovanni Targher
Journal:  Nat Rev Endocrinol       Date:  2022-07-15       Impact factor: 47.564

4.  Does NAFLD mediate the relationship between obesity and type 2 diabetes risk? evidence from the multi-ethnic study of atherosclerosis (MESA).

Authors:  Luis A Rodriguez; Alka M Kanaya; Stephen C Shiboski; Alicia Fernandez; David Herrington; Jingzhong Ding; Patrick T Bradshaw
Journal:  Ann Epidemiol       Date:  2021-07-19       Impact factor: 3.797

5.  Advanced liver fibrosis and the metabolic syndrome in a primary care setting.

Authors:  Andrew D Schreiner; Jingwen Zhang; Valerie Durkalski-Mauldin; Sherry Livingston; Justin Marsden; John Bian; Patrick D Mauldin; William P Moran; Don C Rockey
Journal:  Diabetes Metab Res Rev       Date:  2021-04-09       Impact factor: 4.876

Review 6.  The complex link between NAFLD and type 2 diabetes mellitus - mechanisms and treatments.

Authors:  Giovanni Targher; Kathleen E Corey; Christopher D Byrne; Michael Roden
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-05-10       Impact factor: 46.802

7.  Predicting Non-Alcoholic Fatty Liver Disease for Adults Using Practical Clinical Measures: Evidence from the Multi-ethnic Study of Atherosclerosis.

Authors:  Luis A Rodriguez; Stephen C Shiboski; Patrick T Bradshaw; Alicia Fernandez; David Herrington; Jingzhong Ding; Ryan D Bradley; Alka M Kanaya
Journal:  J Gen Intern Med       Date:  2021-01-26       Impact factor: 6.473

Review 8.  COVID-19 and pediatric fatty liver disease: Is there interplay?

Authors:  Anna Di Sessa; Francesca Lanzaro; Sarah Zarrilli; Vittorio Picone; Stefano Guarino; Emanuele Miraglia Del Giudice; Pierluigi Marzuillo
Journal:  World J Gastroenterol       Date:  2021-06-14       Impact factor: 5.742

9.  Colonoscopy and Risk of Colorectal Cancer in Patients With Nonalcoholic Fatty Liver Disease: A Retrospective Territory-Wide Cohort Study.

Authors:  Xinrong Zhang; Vincent Wai-Sun Wong; Terry Cheuk-Fung Yip; Yee-Kit Tse; Lilian Yan Liang; Vicki Wing-Ki Hui; Guan-Lin Li; Henry Lik-Yuen Chan; Grace Lai-Hung Wong
Journal:  Hepatol Commun       Date:  2021-03-21

10.  Association between nonalcoholic fatty liver disease and incident diabetes mellitus among Japanese: a retrospective cohort study using propensity score matching.

Authors:  Xiaodan Zheng; Changchun Cao; Yongcheng He; Xinyu Wang; Jun Wu; Haofei Hu
Journal:  Lipids Health Dis       Date:  2021-06-15       Impact factor: 3.876

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.